Francisco Leon
Founder bei PROVENTION BIO, INC.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Pilar Perez-Romero | M | - |
Vaxdyn SL
Vaxdyn SL BiotechnologyHealth Technology Vaxdyn SL discovers and develops antigens. Its products include pipeline, clinical need and R&D programs. The company was founded by Jeronimo Pachon, Pilar Perez-Romero and Michael J. McConnell in 2011 and is headquartered in Seville, Spain. | - |
Michael Tolpa | M | - | - | |
Michael McConnell | M | - |
Vaxdyn SL
Vaxdyn SL BiotechnologyHealth Technology Vaxdyn SL discovers and develops antigens. Its products include pipeline, clinical need and R&D programs. The company was founded by Jeronimo Pachon, Pilar Perez-Romero and Michael J. McConnell in 2011 and is headquartered in Seville, Spain. | 13 Jahre |
Debora Pellicano | F | - | 1 Jahre | |
Eleanor Ramos | M | 67 | 7 Jahre | |
Ángel Cebolla Ramirez | M | - |
Glutenostics LLC
Glutenostics LLC Electronic Equipment/InstrumentsElectronic Technology Glutenostics LLC engages in the manufacture of urine and stool test products and retail through online. The company was founded by Angel Cebolla Ramirez and Francisco Leon in 2016 and is headquartered in Los Angeles, CA. | 8 Jahre |
Juan José Infante | M | - |
Vaxdyn SL
Vaxdyn SL BiotechnologyHealth Technology Vaxdyn SL discovers and develops antigens. Its products include pipeline, clinical need and R&D programs. The company was founded by Jeronimo Pachon, Pilar Perez-Romero and Michael J. McConnell in 2011 and is headquartered in Seville, Spain. | 11 Jahre |
Olivier Bogillot | M | - | 1 Jahre | |
Michael Mahla | M | - |
Sidney Kimmel Medical College
| - |
Miguel Sanjuan | M | - | - | |
Jay L. Federman | M | 86 |
Sidney Kimmel Medical College
| - |
Edmund Pribitkin | M | - |
Sidney Kimmel Medical College
| - |
Thomas Klumpp | M | - |
Sidney Kimmel Medical College
| - |
Sarah O'Brien | F | - | 2 Jahre | |
Justin Vogel | M | 52 | 6 Jahre | |
Kristen Kelleher | F | - | - | |
Kaelan Hollon | F | - | - | |
Chad A. Krueger | M | - |
Sidney Kimmel Medical College
| - |
Jan Hillson | M | 71 | 3 Jahre | |
Anthony J. Garramone | M | - |
Glutenostics LLC
Glutenostics LLC Electronic Equipment/InstrumentsElectronic Technology Glutenostics LLC engages in the manufacture of urine and stool test products and retail through online. The company was founded by Angel Cebolla Ramirez and Francisco Leon in 2016 and is headquartered in Los Angeles, CA. | - |
Alex Rabiee | M | - | 5 Jahre | |
Scott Arthur Waldman | M | 71 |
Sidney Kimmel Medical College
| - |
Ricardo Henriques | M | - |
Vaxdyn SL
Vaxdyn SL BiotechnologyHealth Technology Vaxdyn SL discovers and develops antigens. Its products include pipeline, clinical need and R&D programs. The company was founded by Jeronimo Pachon, Pilar Perez-Romero and Michael J. McConnell in 2011 and is headquartered in Seville, Spain. | - |
Julia Haller | M | 69 |
Sidney Kimmel Medical College
| - |
Peter R. Kowey | M | - |
Sidney Kimmel Medical College
| - |
David Winternheimer | M | - |
Glutenostics LLC
Glutenostics LLC Electronic Equipment/InstrumentsElectronic Technology Glutenostics LLC engages in the manufacture of urine and stool test products and retail through online. The company was founded by Angel Cebolla Ramirez and Francisco Leon in 2016 and is headquartered in Los Angeles, CA. | - |
Douglas Jacobstein | M | - | 5 Jahre | |
María del Pilar de la Huerta Martínez | F | 55 |
Vaxdyn SL
Vaxdyn SL BiotechnologyHealth Technology Vaxdyn SL discovers and develops antigens. Its products include pipeline, clinical need and R&D programs. The company was founded by Jeronimo Pachon, Pilar Perez-Romero and Michael J. McConnell in 2011 and is headquartered in Seville, Spain. | - |
Steven C. Halbert | M | - |
Sidney Kimmel Medical College
| - |
Benedict Osorio | M | 67 | 3 Jahre | |
Arthur Michael Feldman | M | - |
Sidney Kimmel Medical College
| - |
Santiago Pla | M | - |
Vaxdyn SL
Vaxdyn SL BiotechnologyHealth Technology Vaxdyn SL discovers and develops antigens. Its products include pipeline, clinical need and R&D programs. The company was founded by Jeronimo Pachon, Pilar Perez-Romero and Michael J. McConnell in 2011 and is headquartered in Seville, Spain. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Wendy Perrow | F | 66 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | 8 Jahre |
Bruce Peacock | M | 72 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | - |
Ashleigh Palmer | M | 61 | 7 Jahre | |
Wayne Pisano | M | 69 | 5 Jahre | |
Anthony DiGiandomenico | M | 57 | 3 Jahre | |
John Jenkins | M | 66 | 3 Jahre | |
Jeffrey Church | M | 67 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | 3 Jahre |
Avery Catlin | M | 75 | 5 Jahre | |
Heidy Abreu King-Jones | F | 41 | 3 Jahre | |
Nancy Wysenski | F | 66 | 3 Jahre | |
Sean N. Doherty | M | 55 | 3 Jahre | |
Jeffrey Bluestone | M | 70 | 3 Jahre | |
Christina Yi | F | 48 | - | |
Sherron Kell | M | - | 2 Jahre | |
Jason Hoitt | M | 46 | 3 Jahre | |
Mark Rigby | M | - | 2 Jahre | |
Edith Mitchell | M | 76 |
Sidney Kimmel Medical College
| - |
Rita Jain | M | 61 | - | |
Cameron Gray | M | 53 | 2 Jahre | |
Mark Ginski | M | - |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | 4 Jahre |
Robert A. Doody | M | - | 1 Jahre | |
Andrew Drechsler | M | 52 | 4 Jahre | |
Thierry Chauche | M | 48 | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 49 | 89,09% |
Spanien | 6 | 10,91% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Francisco Leon
- Persönliches Netzwerk